Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma

Annals of Hematology

Volumn 81, Issue 3, 2002, Pages 140-146

  Wakao, D ^a   Murohashi, I ^a   Tominaga, K ^b   Yoshida, K ^a   Kishimoto, K ^a   Yagasaki, F ^a   Itoh, Y ^a   Itoh, K ^b   Sakata, T ^a   Kawai, N ^a   Kayano, H ^a   Suzuki, T ^b   Matsuda, A ^a   Hirashima, K ^a   Bessho, M ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

Logarithmic linear increase; Proliferation of lymphoma cells; Recurrence; Soluble interleukin 2 receptor; Thymidine kinase

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNISONE; THYMIDINE KINASE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; ENZYME BLOOD LEVEL; FEMALE; HODGKIN DISEASE; HUMAN; LINEAR REGRESSION ANALYSIS; LYMPHOMA; LYMPHOMA CELL; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; SOLUBILITY; T CELL LYMPHOMA;

ADULT; AGED; FEMALE; FORECASTING; HUMANS; INFECTION; KINETICS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, INTERLEUKIN-2; SOLUBILITY; THYMIDINE KINASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036935080     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-001-0421-8     Document Type: Article

References (25)

1. Gronowitz IS, Hagberg H, Kallander CF, Simonsson B (1983) The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47:487-495
2. Martinsson U, Glimelius B, Hagberg H, Sundstrom C (1988) Prognostic relevance of serum-marker, in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin's lymphoma. Eur J Haematol 40:289-298
3. Rehn S, Gronowitz JS, Kallander CF, Sundstrom C, Glimelius B (1995) Deoxythymidine kinase in the tumor cells and serum of patients with non-Hodgkin's lymphoma. Br J Cancer 71:1099-1105
4. Lehtinen T (1988) Correlation between tumor proliferation and serum levels of β2-microglobulin and thymidine kinase in malignant lymphomas. Cancer Detect Prev 12:125-131
5. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek I, Emmerich B (1996) Serum β2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22:439-447
6. Rehn S, Glimelius B, Sundstrom C (1991) A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma. Hematol Oncol 9:287-298
7. Suki S, Swan F Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, Sarris AH, Younes A, Cabanillas F (1995) Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 8:87-92
8. Eriksson B, Hagberg H, Glimelius B, Sundström C, Gronowitz S, Kallander CF (1985) Serum thymidine kinase as a prognostic marker in Hodgkin's disease. Acta Radiol Oncol 24:167-171
9. Sadamori N, Ichiba M, Mine M, Hakariya S, Hayashibara T, Itoyama T, Nakamura H, Tomonaga M, Hayashi K (1995) Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. Br J Cancer 90:100-105
10. Chilosi M, Semenzato G, Vintante F, Menestrina F, Piazzola E, Focchiatti V, Sabbioni R, Zanotti R, Pizzolo G (1989) Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphoma. Am J Clin Pathol 92:186-191
11. Motokura T, Kobayashi Y, Fujita A, Nakamura Y, Taniguchi T, Uchimaru K, Asano A (1995) Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymphoma 16:355-362
12. Gause A, Jung W, Schmits R, Tshiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V, Pfreundschuh M (1992) Soluble CD8, CD25, and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 4:49-52
13. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M (1994) Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 3:2753-2758
14. Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 5:1262-1274
15. Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V, Pfreundschuh M (1991) Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol 2:43-47
16. The international non-Hodgkin's lymphoma prognostic factors project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
17. Harris NL, Jaffe ES, Diebold J, Flandrin G (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207
18. Skeel RT (1995) Biologic and pharmacologic basis of cancer chemotherapy. In: Skeel RT, Lachant NA (eds) Hand book of cancer chemotherapy. Little Brown, Boston, pp 3-13
19. Morrison SJ, Shah NM, and Anderson DJ (1997) Regulatory mechanisms in stem cell biology. Cell 88:287-298
20. Bello LJ (1974) Regulation of thymidine kinase in human cells. Exp Cell Res 89:263-274
21. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263:8350-8358
22. Heaney ML, Golde DW (1996) Soluble cytokine receptors. Blood 87:847-857
23. Smith KA (1988) Interleukin-2: inception, impact and implications. Science 240:1169-1176
24. Voss SD, Sondel PM, Robb RJ (1992) Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vitro by IL-2. J Exp Med 176:531-541
25. Dukovich M, Wano Y, Le-thi-Bich T, Katz P, Cullen BR, Kehrl J H, and Greene WC (1987) A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature 327:518-522